Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls.

MLA

Alvarez, Enrique, et al. “Brain Atrophy Rates in Patients with Multiple Sclerosis on Long Term Natalizumab Resembles Healthy Controls.” Multiple Sclerosis and Related Disorders, vol. 55, Oct. 2021, p. 103170. EBSCOhost, https://doi.org/10.1016/j.msard.2021.103170.

APA

Alvarez, E., Nair, K. V., Hoyt, B. D., Seale, R. A., Sillau, S., Miravalle, A., Engebretson, E., Schurr, B., Corboy, J. R., Vollmer, T. L., & Honce, J. M. (2021). Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls. Multiple Sclerosis and Related Disorders, 55, 103170. https://doi.org/10.1016/j.msard.2021.103170

Chicago

Alvarez, Enrique, Kavita V Nair, Brian D Hoyt, Rebecca A Seale, Stefan Sillau, Augusto Miravalle, Eric Engebretson, et al. 2021. “Brain Atrophy Rates in Patients with Multiple Sclerosis on Long Term Natalizumab Resembles Healthy Controls.” Multiple Sclerosis and Related Disorders 55 (October): 103170. doi:10.1016/j.msard.2021.103170.